BioSpace News Archive

Mahana Therapeutics, a leading developer of prescription digital therapeutics designed to empower people living with chronic health conditions, today announced that Mahana has been selected for the DigitalHealth.London’s Accelerator programme.

Galapagos NV (Euronext & Nasdaq: GLPG) announced today that the Medicines and Healthcare products Regulatory Agency (MHRA) has granted a marketing authorization for Jyseleca®(filgotinib 200mg tablets), as a new treatment for ulcerative colitis (UC) for Great Britain.

STRATA Skin Sciences, Inc. announced that it has entered into an agreement with JuvenIL, the dermatology and aesthetics portion of Trimaco, a leading distributor in Israel for medical devices and innovation, to supply STRATA’s XTRAC® excimer lasers in Israel.

Nabriva Therapeutics plc announced that it adjourned, without conducting any business, its extraordinary general meeting of shareholders on January 18, 2022 to allow the Company to solicit from its shareholders the additional proxies necessary to obtain approval of the proposal described in the Company’s definitive proxy statement filed with the Securities and Exchange Commission on November 22, 2021.

JenaValve Technology, Inc., developer and manufacturer of differentiated transcatheter aortic valve replacement systems, announced a strategic investment and exclusive technology licensing agreement with Peijia Medical Limited in China.

Chimerix today announced that a peer-reviewed article entitled, “Phase 2 Study of ONC201 in Neuroendocrine Tumors including Pheochromocytoma-Paraganglioma (PC-PG) and Desmoplastic Small Round Cell Tumor (DSRCT),” has been published in the journal, Clinical Cancer Research.

Arena Pharmaceuticals, Inc. announced that the Compensation Committee of its Board of Directors granted inducement restricted stock units to new employees.

Fusion Pharmaceuticals Inc., a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, announced that the compensation committee of the Company’s Board of Directors granted stock option awards to purchase an aggregate of 119,000 shares of its common stock to one employee outside Fusion’s 2020 Stock Option and Incentive Plan.

Rocket Lab now operates the world’s largest production line of high-performing space solar cells.

A2 Biotherapeutics, Inc. is a biotechnology company focused on the development of a first-in-class, logic-gated Tmod™ CAR T cell therapy platform to tackle the fundamental challenge in solid tumor treatment—the ability of cancer medicines to distinguish between tumor and normal cells.